Havana_ Institutions affiliated with Cuba's Biotechnology Industry Group and BioCubaFarma are working on the search for new vaccines, with some showing positive signs of security and effectiveness in preclinical and clinical trials, Prensa Latina publishes.

Among the innovations there is a quadrivalent formula for dengue, being investigated at the Genetic Engineering and Biotechnology Center.

Researchers based at the Finlay Institute are working in some solutions for tuberculosis as well as a promising 7-valent conjugate vaccine to protect against pneumococcus being studied by specialists at the Molecular Chemistry Center.

Given the innovative nature of these advances, the developers of the three vaccines were awarded National Academy of Science prizes in 2015 in 5the category of Biomedical Sciences.

Also in the final stages of clinical trials is a cholera vaccine, on which the Finlay Institute, the Scientific Research National Center, and  BioCubaFarma are working jointly.

BioCubaFarma currently produces 10 of the 13 vaccines used in Cuba's national vaccination program, an effort which has eliminated nine diseases and has kept five others under control with very low rates of infection.

One of the most significant impacts of the country's vaccination program has been the control of hepatitis B. No severe cases in children under five years of age have appeared in the country since 1999.

Compartir / Share